Bone Fragility in Diabetes and Its Management: A Narrative Review

Overview

Journal Drugs

Specialty Pharmacology

Date 2024 Aug 5

PMID 39103693

Authors

David Suphadetch Leungsuwan

Manju Chandran

Affiliations

Soon will be listed here.

Abstract

Bone fragility is a serious yet under-recognised complication of diabetes mellitus (DM) that is associated with significant morbidity and mortality. Multiple complex pathophysiological mechanisms mediating bone fragility amongst DM patients have been proposed and identified. Fracture risk in both type 1 diabetes (T1D) and type 2 diabetes (T2D) continues to be understated and underestimated by conventional risk assessment tools, posing an additional challenge to the identification of at-risk patients who may benefit from earlier intervention or preventive strategies. Over the years, an increasing body of evidence has demonstrated the efficacy of osteo-pharmacological agents in managing skeletal fragility in DM. This review seeks to elaborate on the risk of bone fragility in DM, the underlying pathogenesis and skeletal alterations, the approach to fracture risk assessment in DM, management strategies and therapeutic options.

Citing Articles

Risk factors for osteoporosis in elderly patients with type 2 diabetes: A protocol for systematic review and meta-analysis.

Su W, Jia H, Yang L, Zhang J, Wei Z, Tsikwa P PLoS One. 2025; 20(2):e0319602.

PMID: 40014597 PMC: 11867315. DOI: 10.1371/journal.pone.0319602.

References

Bommer C, Heesemann E, Sagalova V, Manne-Goehler J, Atun R, Barnighausen T . The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 2017; 5(6):423-430. DOI: 10.1016/S2213-8587(17)30097-9. View

Cooper C, Campion G, Melton 3rd L . Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992; 2(6):285-9. DOI: 10.1007/BF01623184. View

Gullberg B, Johnell O, Kanis J . World-wide projections for hip fracture. Osteoporos Int. 1997; 7(5):407-13. DOI: 10.1007/pl00004148. View

Lewiecki E, Ortendahl J, Vanderpuye-Orgle J, Grauer A, Arellano J, Lemay J . Healthcare Policy Changes in Osteoporosis Can Improve Outcomes and Reduce Costs in the United States. JBMR Plus. 2019; 3(9):e10192. PMC: 6808223. DOI: 10.1002/jbm4.10192. View

Chandran M, Lau T, Gagnon-Arpin I, Dobrescu A, Li W, Leung M . The health and economic burden of osteoporotic fractures in Singapore and the potential impact of increasing treatment rates through more pharmacological options. Arch Osteoporos. 2019; 14(1):114. DOI: 10.1007/s11657-019-0664-4. View

Haentjens P, Magaziner J, Colon-Emeric C, Vanderschueren D, Milisen K, Velkeniers B . Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med. 2010; 152(6):380-90. PMC: 3010729. DOI: 10.7326/0003-4819-152-6-201003160-00008. View

Hu F, Jiang C, Shen J, Tang P, Wang Y . Preoperative predictors for mortality following hip fracture surgery: a systematic review and meta-analysis. Injury. 2011; 43(6):676-85. DOI: 10.1016/j.injury.2011.05.017. View

Voko Z, Gaspar K, Inotai A, Horvath C, Bors K, Speer G . Osteoporotic fractures may impair life as much as the complications of diabetes. J Eval Clin Pract. 2017; 23(6):1375-1380. DOI: 10.1111/jep.12800. View

Chandran M, Aftab N, Amin A, Amphansap T, Bhadada S, Chadha M . Evaluating compliance with the care standard of proactively assessing bone health in patients with diabetes: a pilot audit of practice across Asia by the Asia Pacific Consortium on Osteoporosis (APCO). Arch Osteoporos. 2024; 19(1):48. PMC: 11166814. DOI: 10.1007/s11657-024-01399-y. View

10.

Rasmussen N, Dal J, van den Bergh J, de Vries F, Jensen M, Vestergaard P . Increased Risk of Falls, Fall-related Injuries and Fractures in People with Type 1 and Type 2 Diabetes - A Nationwide Cohort Study. Curr Drug Saf. 2020; 16(1):52-61. DOI: 10.2174/1574886315666200908110058. View

11.

Rasmussen N, Dal J, Jensen M, Kvist A, van den Bergh J, Hirata R . Impaired postural control in diabetes-a predictor of falls?. Arch Osteoporos. 2022; 18(1):6. DOI: 10.1007/s11657-022-01188-5. View

12.

Takamoto I, Kadowaki T . [Diabetes and osteoporosis]. Clin Calcium. 2004; 14(2):255-61. DOI: CliCa0402255261. View

13.

Ebeling P, Nguyen H, Aleksova J, Vincent A, Wong P, Milat F . Secondary Osteoporosis. Endocr Rev. 2021; 43(2):240-313. DOI: 10.1210/endrev/bnab028. View

14.

Wukich D, Joseph A, Ryan M, Ramirez C, Irrgang J . Outcomes of ankle fractures in patients with uncomplicated versus complicated diabetes. Foot Ankle Int. 2011; 32(2):120-30. DOI: 10.3113/FAI.2011.0120. View

15.

Humphers J, Shibuya N, Fluhman B, Jupiter D . The impact of glycosylated hemoglobin and diabetes mellitus on wound-healing complications and infection after foot and ankle surgery. J Am Podiatr Med Assoc. 2014; 104(4):320-9. DOI: 10.7547/0003-0538-104.4.320. View

16.

Norris R, Parker M . Diabetes mellitus and hip fracture: a study of 5966 cases. Injury. 2011; 42(11):1313-6. DOI: 10.1016/j.injury.2011.03.021. View

17.

Brauer C, Coca-Perraillon M, Cutler D, Rosen A . Incidence and mortality of hip fractures in the United States. JAMA. 2009; 302(14):1573-9. PMC: 4410861. DOI: 10.1001/jama.2009.1462. View

18.

Abrahamsen B, Skjodt M, Vestergaard P . Hip fracture rates and time trends in use of anti-osteoporosis medications in Denmark for the period 2005 to 2015: Missed opportunities in fracture prevention. Bone. 2018; 120:476-481. DOI: 10.1016/j.bone.2018.12.016. View

19.

Nasser M, Kvist A, Vestergaard P, Eastell R, Burden A, Frost M . Sex- and Age Group-Specific Fracture Incidence Rates Trends for Type 1 and 2 Diabetes Mellitus. JBMR Plus. 2023; 7(11):e10836. PMC: 10652176. DOI: 10.1002/jbm4.10836. View

20.

Kvist A, Nasser M, Vestergaard P, Frost M, Burden A . Site-Specific Fracture Incidence Rates Among Patients With Type 1 Diabetes, Type 2 Diabetes, or Without Diabetes in Denmark (1997-2017). Diabetes Care. 2023; 46(3):633-642. PMC: 10020021. DOI: 10.2337/dc22-1004. View